During his career, Mr. Gleeson has been a key party to building more than 20 biomedical companies from breakthrough research and technologies and has negotiated numerous financing and M&A transactions valued in excess of $500 million. Prior to co-founding Satellos, he and Dr. Rudnicki co-founded Verio Therapeutics, where Mr. Gleeson was CEO and managed the acquisition by Fate Therapeutics (Nasdaq: FATE). Previous to Verio, he was Chief Commercial Operations at Centre for Probe Development and Commercialization (CPDC), where he played a principal role in building a global radiopharmaceutical manufacturing business and supporting the creation of two spin-out companies. Prior to CPDC, he served as an Executive-in-Residence with the Fight Against Cancer Innovation Trust (FACIT), an innovative nucleator, where he supported or led the creation, financing and exits of three new entities. Previously, Mr. Gleeson was founding CEO of MDS Proteomics Inc., where he made and integrated three acquisitions, built leading-edge sequencing infrastructure, a 200-person team, and raised in excess of $100 million. He was also Senior Vice President and Venture Partner with MDS Capital Corp. (now Lumira), where he was lead partner on a fund with more than $250 million under management focused on creating drug discovery companies based on novel Canadian science. Prior to his tenure with MDS, he enjoyed a 17-year operational career with ICI plc (now AstraZeneca), a global chemicals, pharmaceuticals, and advanced materials company, during which he was involved in technology commercialization in several fields both in Canada and internationally. Mr. Gleeson has served on numerous boards of private and public companies and not-for-profit entities.